ASX Releases
To access ASX releases prior to those listed below please visit the ASX Website and enter our ASX Code BTA.
2006
- Clarification of Canadian Gov't order of Relenza 20 December 2006
- ASX Appendix 3Y: Directors' Interest - P Cook 14 December 2006
- ASX Appendix 3B: New Issue Announcement 14 December 2006
- Ireland orders 706,000 courses of Relenza 11 December 2006
- ASX Appendix 3Y: Directors' Interest - G Latta 8 December 2006
- ASX Appendix 3B: New Issue Announcement 29 November 2006
- Open Briefing - CEO on HCV Licensing Agreement 27 November 2006
- Biota completes US$102m HCV licence 27 November 2006
- Substantial Shareholder Notice 22 November 2006
- Canada orders 5.5m courses of Relenza 10 November 2006
- Substantial Shareholder Notice 27 October 2006
- ASX Appendix 3B: New Issue Announcement 27 October 2006
- Q1 Royalties from Relenza hits $5.3m 27 October 2006
- 2006 Annual General Meeting Results 25 October 2006
- 2006 Annual General Meeting Addresses 25 October 2006
- GSK License Grant 29 September 2006
- Substantial Shareholder Notice 25 September 2006
- Notice of Meeting AGM 2006 19 September 2006
- Substantial Shareholder Notice 18 September 2006
- Biota appoints new Director 8 September 2006
- App3Y P Bell 8 September 2006
- Full Year Results 6 September 2006
- Open Briefing - CEO on Results and Outlook 6 September 2006
- Supreme Court sets Trial date 30 August 2006
- Relenza Approvals Extended in EU 25 August 2006
- HRV commences Phase Ib Clinical Trial 17 August 2006
- New Issue 9 August 2006
- US$8.5m award for FLUNET 8 August 2006
- HRV completes Phase Ia Clinical Trial 2 August 2006
- Relenza sales increase substantially 27 July 2006
- US Govt orders US$16.8m courses of Relenza 21 July 2006
- Substantial Shareholder Notice 11 July 2006
- US intention to order further courses of Relenza 3 July 2006
- Options Lapsed 30 June 2006
- Shareholder Letter - GSK litigation 30 June 2006
- ASX Appendix 3B: New Issue Announcement 16 June 2006
- Substantial Shareholder Notice 29 May 2006
- Relenza - Prophylaxis approval in Australia 1 May 2006
- US Department of Defense order US$5.2m of Relenza 19 April 2006
- Biota appoints Vice President Business Development 6 April 2006
- Relenza wins additional US Federal Approval 30 March 2006
- Sankyo to market next generation influenza treatem 29 March 2006
- US Health Dept orders further 2.2m courses 23 March 2006
- Half year Report - 31 December 2005 3 March 2006
- Biota added to S&P ASX 300 3 March 2006
- US Health Dept orders 1.75m additional courses 2 March 2006
- Biota awarded Pandemic Influenza Grant 20 February 2006
- Biota Commences Phase 1 Clinical Trials 16 February 2006
- Biota appoints new Director 9 February 2006
- App3Y G Latta 9 February 2006
